[Four departments: Individual discussion on supporting independent declaration of special cases by medical institutions for cases of rational use of innovative drugs in the national medical insurance catalog that are not suitable for payment according to disease type] On November 10, the National Health Commission, the National Medical Insurance Administration, the State Administration of Traditional Chinese Medicine, and the National Administration of Disease Control and Prevention issued the "Notice on Further Improving the Safe and Reasonable Distribution and Use of Innovative Drugs" on the 10th. It is proposed that local medical insurance departments should implement pharmaceutical-related medical service price items to fully reflect the value of pharmaceutical services. For cases that reasonably use innovative drugs in the national medical insurance catalog and are not suitable for payment according to the disease type payment standards, medical institutions are supported to independently declare special cases for independent negotiation. The medical insurance department should simplify and optimize procedures, organize experts to evaluate special individual cases on a quarterly or monthly basis, and implement project-based payment for relevant cases or adjust the payment standards for the case based on the evaluation results. Cases using drugs in the innovative drug catalog of commercial health insurance may not be included in the scope of medical insurance payment by disease type, and will be paid after review and evaluation procedures.